COVID-19 and toxicity from potential treatments: Panacea or poison.
Emerg Med Australas
; 32(4): 697-699, 2020 08.
Article
en En
| MEDLINE
| ID: mdl-32378805
Since December 2019, coronavirus disease (COVID-19) has been increasingly spreading from its origin in Wuhan, China to many countries around the world eventuating in morbidity and mortality affecting millions of people. This pandemic has proven to be a challenge given that there is no immediate cure, no vaccine is currently available and medications or treatments being used are still undergoing clinical trials. There have already been examples of self-medication and overdose. Clearly, there is a need to further define the efficacy of treatments used in the management of COVID-19. This evidence needs to be backed by large randomised-controlled clinical trials. In the meantime, there will no doubt be further off-label use of these medications by patients and practitioners and possibly related toxicity.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Neumonía Viral
/
Infecciones por Coronavirus
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Emerg Med Australas
Asunto de la revista:
MEDICINA DE EMERGENCIA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Australia
Pais de publicación:
Australia